Aktie im Blick: Bayer zelebriert Börsen-Mathematik, die Aktionäre kennen sollten

Bayer is on track to become the biggest winner in 2026 according to analysts, with its share price soaring by over 100% in the past year alone. The company is currently the strongest stock in both the Dax and Euro Stoxx 50 indices, having nearly tripled in price since early 2025. However, it still needs to regain its all-time high reached in April 2015, when investors paid up to 145.80 euros for a single share.

That price represents a 673.5% increase from its current level, highlighting the dramatic drop Bayer experienced after acquiring Monsanto in 2018. The controversial pesticide manufacturer's product, glyphosate, led to a wave of lawsuits in the US, causing the stock to plummet by up to 87% in the following decade. Despite this turbulent past, Bayer's share price has risen by more than 200% since then.

To return to its former value, the stock would need to surge by nearly 674%. The company has set new annual targets, driven by positive developments such as the approval of its new stroke treatment, Asundexian, and its promising cancer drug, Nubeqa. In the first three quarters of the year, Bayer reported net earnings of 5.2 billion euros, up from a billion euros in the same period last year.

The introduction of new medications and the impact of patent expirations are helping to offset revenue losses. CEO Bill Anderson is restructuring the company, cutting 12,000 jobs across its agriculture, pharmaceutical, and consumer health segments to streamline operations. The Monsanto lawsuit, which could have cost Bayer billions, appears to be winding down with a recent favorable ruling that eliminates the need for plaintiffs to prove Monsanto warned about the cancer risks of its glyphosate-based product.

Analysts are generally optimistic about Bayer's prospects, with 16 out of 21 recommending buying the stock, citing its current valuation as reasonable despite the strong price increase.